IDXXNASDAQ— IDEXX Laboratories Inc Price & Analysis

IDEXX Laboratories Inc

HEALTHCARE — DIAGNOSTICS & RESEARCH

$560.38

-$6.38-1.13%

Market Cap: $44.65B; Large Cap
P/E Ratio: 38.9; Fwd: 31.45
EPS (TTM): $14.57
Div. Yield: N/A

Technical Summary

RSI (14)61.92Neutral

SMA (50)$533.01Bullish

SMA (200)$576.39Bearish

MACD9.0113Bullish

Bollinger$496.72 – $570.91Mid

Stochastic87.93Overbought

Theo Outlook

IDEXX Laboratories develops, manufactures, and distributes products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. For the twelve months ended June 30, 2026, it reported revenue of $4.55 billion, a profit margin of 25%, an operating margin of 35%, and diluted earnings per share of $14.57. Its market capitalization stood at $44.65 billion.

Bull case: Revenue grew 9.7% year over year in the latest quarter while earnings grew 17.6% year over year, and return on equity reached 74.2%. Bear case: The trailing price-to-earnings ratio is 38.9 and the price-to-sales ratio is 9.81, while the forward price-to-earnings ratio is 31.45.

The company faces risks from its concentration in veterinary diagnostics and related markets. Analysis generated by HeyTheo AI from company and market data. It may be incomplete or inaccurate.

Analysis generated by HeyTheo AI on Oct 23, 2026.

Company Overview

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Fundamental Snapshot

Revenue: $4.55B
EBITDA: $1.62B
Gross Profit: $2.84B
Operating Margin: 35.0%
Profit Margin: 25.0%
ROE: 74.2%
Book Value: $20.45
Beta: 1.55
52-Wk High: $769.98
52-Wk Low: $500.61
Volume: 397.29K
PEG Ratio: 2.85

Frequently Asked Questions

What does IDEXX Laboratories do?

Where does IDEXX Laboratories's revenue come from?

IDEXX Laboratories generates revenue from products and services in companion animal veterinary, livestock and poultry, water testing, and dairy markets. Revenue reached $4.55 billion for the twelve months ended June 30, 2026, with quarterly revenue growth of 9.7% year over year.

How does IDEXX Laboratories compete?

IDEXX Laboratories competes through its specialized diagnostics and testing solutions across veterinary and related markets. It achieved an operating margin of 35% and return on equity of 74.2% for the twelve months ended June 30, 2026.

What are the main risks for IDEXX Laboratories?

IDEXX Laboratories faces risks from concentration in veterinary diagnostics and related sectors. Quarterly earnings grew 17.6% year over year as of the latest quarter ended June 30, 2026.

How is IDEXX Laboratories valued?

The trailing price-to-earnings ratio stood at 38.9, the forward price-to-earnings ratio at 31.45, the price-to-sales ratio at 9.81, and the price-to-book ratio at 25.48 as of the latest quarter ended June 30, 2026.